Introduction: The optimal management for patients with diabetes and peripheral vascular
INTRODUCTION
The International Diabetes Federation estimates more than 387 million people worldwide were affected by diabetes in 2014, with this number predicted to rise to 592 million by 2035 [1] . Diabetes-related foot disease, in particular foot ulcers, remains one of the main complications caused by a combination of peripheral neuropathy, infection, and peripheral arterial disease (PAD) [2] . Recent data have shown that diabetes is second only to smoking as a cause of PAD [3] . More than one million people a year undergo amputation of the lower limb, with 85% of cases precipitated by a foot ulcer [4] . In England, an estimated £639 million to £662 million (0.6-0.7% of the total National Health Service budget) is spent on the treatment of diabetic foot ulceration and amputation [5] . Aside from the economic burden, there are often considerable social and psychological impacts associated with the diagnosis of diabetes [6] .
Infection and PAD form the two major indications for lower limb amputation in diabetes [7, 8] . The Framingham Heart Study (ClinicalTrials.gov identifier, NCT00005121) showed one-fifth of patients with symptomatic PAD suffered also from diabetes, although the actual prevalence is likely to be higher as most cases of PAD are asymptomatic [9] . The most frequently observed presentation of symptomatic PAD is intermittent claudication; described as a reproducible pain or cramp of the lower limb on walking, which is then relieved by rest. At the other end of the spectrum, a minority of patients will present with features of critical limb ischemia (CLI): rest pain, tissue loss with ulceration and gangrene. Of note, in patients with PAD associated with diabetes, the diseased vessel is often distal, (femoro-popliteal and tibial), whereas PAD secondary to other risk factors (e.g., smoking, hypercholesterolemia), generally occurs in more proximal (aorto-ilio-femoral) vessels [6] . PAD, which progresses faster in the population with diabetes, has been shown in large observational studies to complicate up to half of all diabetic foot ulcer cases, and is an independent risk factor for amputation [6, [10] [11] [12] . The prognosis of patients with a diabetic foot ulcer and PAD is poor, with a 50% dying at 5 years, and at 2 years following a major amputation [13] .
The Inter-Society Consensus for the With regards to risk factors for arterial disease, similar proportions of claudicant patients were ex-or current smokers within the medical and surgical treatment groups (62.5% versus 57.1%, respectively). For critical ischemia, there was a higher proportion of exor current smokers for those patients treated surgically (69.2% versus 36.7%).
Analysis of diabetes related risk factors shows the mean glycated hemoglobin (HbA1c) was lower for patients treated medically in the claudicant cohort (54 versus 62 mmol/mol), but higher in critical ischemia patients treated medically (64 versus 56 mmol/mol). In this study, the majority of patients had Type 2 diabetes, with only 4 patients with Type 1. The proportion of patients on insulin therapy compared to diet or tablet alone was similar for both medically and surgically treated patient cohorts in the claudicant arm (25% versus 28.6%, respectively), but was markedly higher for those patients treated medically within the critical ischemia arm (53.3% versus 15.4%).
Review of baseline surgical status showed 42.9% of patients in the claudicant group treated with revascularization had prior surgery compared to 37.5% of patients treated conservatively. For critical ischemia, patients in the revascularization cohort had slightly higher rates of previous surgical intervention (50% The data we present here are descriptive only, with no attempts at statistical analysis due to the small sample size and retrospective nature of the study, which made any further comparisons between the cohorts unreliable.
DISCUSSION
In this study, we demonstrate revascularization to be a more effective treatment for claudicants and patients with CLI, with approximately double the amputation-free survival rate at 5 years. However, our study has also demonstrated similar amputation outcomes at 1-year follow-up for patients treated with either medical or revascularization therapy for both presentations of claudication and CLI.
Our results at 1 year would suggest that conservative management of CLI and claudication is as effective as surgical intervention in terms of limb preservation. For patients, this would mean a similar clinical outcome without the risks and complications of HbA1c glycated hemoglobin, eGFR estimated glomerular filtration rate, STEMI ST segment elevation myocardial infarction, NSTEMI non ST-Segment elevation myocardial infarction, TIA transient ischemic attack, ACE angiotensin-converting enzyme, ARB angiotensin 2 receptor blockers a b Fig. 1 a, b One-year clinical outcome of patients treated by medical versus revascularization for presentations of critical limb ischemia and claudication surgery, and a financial benefit for the health system. Our data are in contrast to previous work that has shown better rates of limb salvage for patients undergoing vascular intervention [18, 19] . The results of these reviews also reflect the current UK national and international guidelines for the management of PADalthough it must be acknowledged that these guidelines are not specific to diabetes [14] . The TASC II and 2012 NICE guidelines on intermittent claudication recommend initial conservative treatment with a supervised exercise program and modification of risk factors, with a plan for angioplasty and possible bypass surgery if these measures prove to be unsuccessful [14, 15] . For CLI, NICE recommends revascularization therapy over conservative measures, as assessed by a dedicated vascular multidisciplinary team [15] .
TASC II is also in favor of revascularization over conservative measures for CLI if the patient is fit for surgery [14] . In addition, the guideline recommends best medical management or amputation if there is intolerable pain or spreading infection [14] . Nevertheless, whilst the findings of the current study are in contrast to these guidelines, they are in accordance with 2 other studies that show that best medical management for the diabetic foot at 1 year is associated with similar outcomes as revascularization [20, 21] . Elgzyri et al.
conducted a prospective study of 602 patients with diabetes who all presented to a multidisciplinary foot center with foot ulcers, but who were deemed to be unsuitable for revascularization [20] . These authors demonstrated limb salvage rates of 56% and 77%, respectively, at 1 year, with significant healing with conservative measures or with minor amputation alone [20, 21] . In addition, larger multicenter trials would also allow subgroup analysis of data. Of interest, the distinction between endovascular procedures and more invasive bypass surgery is a clinically significant one: the endovascular route is less invasive, can be performed under local anesthesia as a day case, and can be performed more than once. Results of subgroup analysis for critical ischemia in this study show comparable one-and 5-year amputation-free survival rates for the two revascularization routes; however, small cohorts make further analysis of data unreliable.
Within the CLI cohort, we recorded also the location of ulcer and gangrene for patients treated by conservative and revascularization (Table 1) . Location was recorded as forefoot (hallux and toes), mid-foot (to include metatarsals, dorsal and plantar surfaces of the foot), heel, ankle, leg or location unavailable.
The majority of such lesions occurred on the forefoot of both treatment arms. The very small numbers of ulcers and gangrene occurring elsewhere in the lower limb make any further analysis of the relationship between location and rate of amputation unreliable.
In addition, as a retrospective study, the data collected are limited to the information already available from previously documented events, rather than prospectively collecting information specific to this study question. Prospective data collection may provide a more detailed account of disease presentation, co-morbidities, and medication history of the patient.
Recent studies show the outcome of a diabetic foot ulcer is not only affected by the severity of ischemia, but also by the extent of tissue loss, the presence of infection, and certain co-morbidities of the patient [24] . For example, there is evidence that the presence of stroke and the microvascular complications of diabetes are strongly associated with lower limb amputation. However, the rate of amputation in patients with and without coronary artery disease and/or myocardial infarction was not significantly different [25, 26] . In our study, despite aggressive revascularization therapy, the 1-year amputation-free survival rate is similar for claudicant patients treated by both medical and surgical approaches. The absence of superiority of revascularization may be partly explained by the differing patient characteristics of the two treatment arms. For example, there is a higher prevalence of previous TIA/stroke (4 versus 0 patients), and a higher mean HbA1c (62 versus 54 mmol/mol), within the cohort treated with revascularization compared to those treated medically. As discussed above, could patients with a history of cerebrovascular disease and poorly controlled diabetes, and therefore, a greater likelihood of microvascular complications, be more likely to progress to amputation regardless of aggressive therapy?
In a similar fashion, patients with chronic kidney disease (eGFR \60 ml/min) and those treated with renal dialysis have a higher rate of below-and above-knee amputations in comparison with diabetic patients without renal disease [27] . In our study, within the group of patients presenting with CLI, the mean eGFR is lower for those patients treated surgically in comparison to those treated medically (53.8 versus 58.4 mL/min/1.73 m 2 ). In our study, the degree of tissue loss, presence of infection, and severity of ischemia were not recorded. The use of randomization or matching techniques to take into account these confounding factors is difficult to perform in our current study population due to the relatively small sample size. Nevertheless, patients with diabetes who have certain co-morbidities associated with higher rates of amputation may warrant an earlier and more intensive treatment approach for long-term limb preservation. In a similar fashion, all patients, whether treated with conservative or surgical measures, would benefit from tight glycemic and blood pressure control to reduce both the microvascular complications and thus rates of lower extremity amputation.
A comment needs to be made about the apparent lack of use of adjuvant therapies (Table 1) , in particular statins, in our cohort. Many of these individuals also had some underlying wound infections. Our standardized antibiotic protocol advocates the use of clarithromycin or fucidin at times [28] .
The use of either of these drugs necessitates the stopping of statin therapy to avoid potential interaction and subsequent rhabdomyolysis. Medical Center [29] . Results of that study suggested some patients-in particular those with dementia-may have had a technically satisfactory outcome, including limb salvage, but may not have experienced any improved functional outcome. That group of patients overall performed worse than those patients who lost their limbs, in terms of survival, ambulation, and independent living [29] .
Thus, despite achieving arterial patency and long-term limb salvage, some patients may still suffer from functional disabilities that result in both a reduced sense of well-being for the individual, as well as a significant financial burden on the healthcare system. In this context, despite similar amputation-free survival rates for our two cohorts at 1 year, it is necessary also to assess how this compares with the functional outcome for our patients in terms of maintenance of mobility and quality of life. Our data are in agreement with recent guidance from the International Working Group of the Diabetic Foot who recommends that ''revascularization should be avoided in patients in whom, from the patient perspective; the risk-benefit ratio for the probability of success is unfavorable'' [30] . In line with the above, it would be interesting to assess length and frequency of hospital admission for the patients in this study as these factors can also have a significant impact on quality of life.
We acknowledge that our data have their limitations. It is retrospective in nature, a relatively small sample size and a relatively short follow-up period. We have also not described in detail the nature of the severity of the PAD. Our study is also similar to previous work because our subjects lack matching between the 2 groups. 
